These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22211478)

  • 21. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.
    Adam HJ; Hoban DJ; Gin AS; Zhanel GG
    Int J Antimicrob Agents; 2009 Jul; 34(1):82-5. PubMed ID: 19342204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia.
    Uchida Y; Mochimaru T; Morokuma Y; Kiyosuke M; Fujise M; Eto F; Harada Y; Kadowaki M; Shimono N; Kang D
    Int J Antimicrob Agents; 2010 Apr; 35(4):387-91. PubMed ID: 20138480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli.
    Stein GE; Schooley SL; Nicolau DP
    Int J Antimicrob Agents; 2008 Oct; 32(4):320-5. PubMed ID: 18715762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.
    Zaytoun OM; Vargo EH; Rajan R; Berglund R; Gordon S; Jones JS
    Urology; 2011 May; 77(5):1035-41. PubMed ID: 21420152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.
    Lautenbach E; Fishman NO; Metlay JP; Mao X; Bilker WB; Tolomeo P; Nachamkin I
    J Infect Dis; 2006 Jul; 194(1):79-85. PubMed ID: 16741885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased prevalence of plasmid-mediated quinolone resistance determinants in chicken Escherichia coli isolates from 2001 to 2007.
    Huang SY; Dai L; Xia LN; Du XD; Qi YH; Liu HB; Wu CM; Shen JZ
    Foodborne Pathog Dis; 2009 Dec; 6(10):1203-9. PubMed ID: 19735206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.
    Sato T; Suzuki Y; Shiraishi T; Honda H; Shinagawa M; Yamamoto S; Ogasawara N; Takahashi H; Takahashi S; Tamura Y; Yokota SI
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
    Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
    New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.
    Karlowsky JA; Adam HJ; Desjardins M; Lagacé-Wiens PR; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i39-46. PubMed ID: 23587777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.
    Gallini A; Degris E; Desplas M; Bourrel R; Archambaud M; Montastruc JL; Lapeyre-Mestre M; Sommet A
    J Antimicrob Chemother; 2010 Dec; 65(12):2650-7. PubMed ID: 20876240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
    Gagliotti C; Buttazzi R; Sforza S; Moro ML;
    J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
    Cranendonk DR; van der Valk M; Langenberg ML; van der Meer JT
    Scand J Infect Dis; 2012 May; 44(5):363-8. PubMed ID: 22200089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates.
    Lin CY; Huang SH; Chen TC; Lu PL; Lin WR; Chen YH
    J Microbiol Immunol Infect; 2008 Aug; 41(4):325-31. PubMed ID: 18787740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular analysis of ciprofloxacin resistance and clonal relatedness of clinical Escherichia coli isolates from haematology patients receiving ciprofloxacin prophylaxis.
    van Hees BC; Tersmette M; Willems RJ; de Jong B; Biesma D; van Hannen EJ
    J Antimicrob Chemother; 2011 Aug; 66(8):1739-44. PubMed ID: 21636586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of minimum inhibitory concentration values for fluoroquinolones against Escherichia coli causing urinary tract infection in both hospitalized patients and outpatients.
    Tayfour M; Yuce A; Yulug N
    Saudi Med J; 2001 Oct; 22(10):848-51. PubMed ID: 11744939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
    Mahamat A; Lavigne JP; Fabbro-Peray P; Kinowski JM; Daurès JP; Sotto A
    Clin Microbiol Infect; 2005 Apr; 11(4):301-6. PubMed ID: 15760427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.